JP2005522495A - 新規な糖尿病イメージングプローブ - Google Patents
新規な糖尿病イメージングプローブ Download PDFInfo
- Publication number
- JP2005522495A JP2005522495A JP2003583570A JP2003583570A JP2005522495A JP 2005522495 A JP2005522495 A JP 2005522495A JP 2003583570 A JP2003583570 A JP 2003583570A JP 2003583570 A JP2003583570 A JP 2003583570A JP 2005522495 A JP2005522495 A JP 2005522495A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- amino
- nhx
- acid
- sulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 17
- 238000003384 imaging method Methods 0.000 title abstract description 20
- 239000000523 sample Substances 0.000 title abstract description 19
- 239000003472 antidiabetic agent Substances 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 34
- 230000005298 paramagnetic effect Effects 0.000 claims abstract description 31
- 230000003178 anti-diabetic effect Effects 0.000 claims abstract description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 31
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 29
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 28
- -1 fluoroacyl Chemical group 0.000 claims description 28
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 25
- 229910052731 fluorine Inorganic materials 0.000 claims description 25
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000011737 fluorine Substances 0.000 claims description 20
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 18
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 14
- 229960003330 pentetic acid Drugs 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 9
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 9
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 9
- 150000002500 ions Chemical class 0.000 claims description 8
- 229920005548 perfluoropolymer Polymers 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000007983 Tris buffer Substances 0.000 claims description 5
- 125000004407 fluoroaryl group Chemical group 0.000 claims description 5
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 5
- JBNOVHJXQSHGRL-UHFFFAOYSA-N 7-amino-4-(trifluoromethyl)coumarin Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(N)=CC=C21 JBNOVHJXQSHGRL-UHFFFAOYSA-N 0.000 claims description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
- 150000004696 coordination complex Chemical group 0.000 claims description 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- UDOPJKHABYSVIX-UHFFFAOYSA-N 2-[4,7,10-tris(carboxymethyl)-6-[(4-isothiocyanatophenyl)methyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CCN(CC(O)=O)C1CC1=CC=C(N=C=S)C=C1 UDOPJKHABYSVIX-UHFFFAOYSA-N 0.000 claims description 3
- GLHBARTVPOQHMV-UHFFFAOYSA-N 2-[4-[2-(4-aminoanilino)-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical group C1=CC(N)=CC=C1NC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 GLHBARTVPOQHMV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052692 Dysprosium Inorganic materials 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 239000004305 biphenyl Substances 0.000 claims description 3
- 235000010290 biphenyl Nutrition 0.000 claims description 3
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 3
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 claims description 2
- ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- KXKHTLYGVLZMGL-UHFFFAOYSA-N 2-[4,10-bis(carboxymethyl)-7-(2-ethoxy-3,4-dioxocyclobuten-1-yl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound O=C1C(=O)C(OCC)=C1N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 KXKHTLYGVLZMGL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052691 Erbium Inorganic materials 0.000 claims description 2
- 229910052693 Europium Inorganic materials 0.000 claims description 2
- 229910052689 Holmium Inorganic materials 0.000 claims description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052771 Terbium Inorganic materials 0.000 claims description 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 2
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 2
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 2
- 150000002602 lanthanoids Chemical class 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- 239000011572 manganese Substances 0.000 claims description 2
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 229910052723 transition metal Inorganic materials 0.000 claims description 2
- 150000003624 transition metals Chemical class 0.000 claims description 2
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 9
- 238000002059 diagnostic imaging Methods 0.000 abstract description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 abstract 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 28
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 27
- 235000019000 fluorine Nutrition 0.000 description 22
- 229940100389 Sulfonylurea Drugs 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 12
- 239000002872 contrast media Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000001153 fluoro group Chemical group F* 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229940058401 polytetrafluoroethylene Drugs 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000032 diagnostic agent Substances 0.000 description 6
- 229940039227 diagnostic agent Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
- 229940072056 alginate Drugs 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005291 magnetic effect Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 4
- 150000008065 acid anhydrides Chemical class 0.000 description 4
- 229940125708 antidiabetic agent Drugs 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001805 chlorine compounds Chemical class 0.000 description 4
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical class FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 4
- 229960004346 glimepiride Drugs 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000009145 protein modification Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- FXNSVEQMUYPYJS-UHFFFAOYSA-N 4-(2-aminoethyl)benzenesulfonamide Chemical compound NCCC1=CC=C(S(N)(=O)=O)C=C1 FXNSVEQMUYPYJS-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000003633 blood substitute Substances 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000003682 fluorination reaction Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 3
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 3
- 229960001217 perflubron Drugs 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- LSKOUPSEWMJCEP-UHFFFAOYSA-N 1,2,3-trifluoro-4-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C(F)=C1F LSKOUPSEWMJCEP-UHFFFAOYSA-N 0.000 description 2
- JTYRBFORUCBNHJ-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br JTYRBFORUCBNHJ-UHFFFAOYSA-N 0.000 description 2
- DAYBSGSKULSMIW-UHFFFAOYSA-N 2-[6-(5-amino-2-methoxyphenyl)-4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound COC1=CC=C(N)C=C1C1N(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)C1 DAYBSGSKULSMIW-UHFFFAOYSA-N 0.000 description 2
- HIMMCCJEMMCUJS-UHFFFAOYSA-N 4-fluorotriazine Chemical compound FC1=CC=NN=N1 HIMMCCJEMMCUJS-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 102000018692 Sulfonylurea Receptors Human genes 0.000 description 2
- 108010091821 Sulfonylurea Receptors Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002118 epoxides Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012025 fluorinating agent Substances 0.000 description 2
- UKZZNMODYJELLV-UHFFFAOYSA-N fluoro carbamate Chemical compound NC(=O)OF UKZZNMODYJELLV-UHFFFAOYSA-N 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- MDQRDWAGHRLBPA-UHFFFAOYSA-N fluoroamine Chemical compound FN MDQRDWAGHRLBPA-UHFFFAOYSA-N 0.000 description 2
- 229920002313 fluoropolymer Polymers 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- RIGBPMDIGYBTBJ-UHFFFAOYSA-N glycyclamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 RIGBPMDIGYBTBJ-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UFFSXJKVKBQEHC-UHFFFAOYSA-N heptafluorobutyric anhydride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(=O)OC(=O)C(F)(F)C(F)(F)C(F)(F)F UFFSXJKVKBQEHC-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 1
- UVWPNDVAQBNQBG-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-icosafluorononane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F UVWPNDVAQBNQBG-UHFFFAOYSA-N 0.000 description 1
- XVKJSLBVVRCOIT-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluoro-10-iododecane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)CCI XVKJSLBVVRCOIT-UHFFFAOYSA-N 0.000 description 1
- KWXGJTSJUKTDQU-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluoro-8-iodooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)I KWXGJTSJUKTDQU-UHFFFAOYSA-N 0.000 description 1
- XYTVKPCMDPOOFB-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,7,7,8,8,9,9,10,10,10-octadecafluorodecane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)CCC(F)(F)C(F)(F)C(F)(F)C(F)(F)F XYTVKPCMDPOOFB-UHFFFAOYSA-N 0.000 description 1
- XTGYEAXBNRVNQU-UHFFFAOYSA-N 1,1,1,2,2,3,3-heptafluoro-3-iodopropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)I XTGYEAXBNRVNQU-UHFFFAOYSA-N 0.000 description 1
- LWRNQOBXRHWPGE-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8a-heptadecafluoro-8-(trifluoromethyl)naphthalene Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(C(F)(F)F)(F)C(F)(F)C(F)(F)C(F)(F)C21F LWRNQOBXRHWPGE-UHFFFAOYSA-N 0.000 description 1
- QXLDBWRLZDBVGF-UHFFFAOYSA-N 1,2,3,4,5-pentafluoro-6-isocyanatobenzene Chemical compound FC1=C(F)C(F)=C(N=C=O)C(F)=C1F QXLDBWRLZDBVGF-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- VPQQZKWYZYVTMU-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,7-pentadecafluoroheptane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br VPQQZKWYZYVTMU-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- NRSSOFNMWSJECS-UHFFFAOYSA-N 1-isocyanato-3,5-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(N=C=O)=CC(C(F)(F)F)=C1 NRSSOFNMWSJECS-UHFFFAOYSA-N 0.000 description 1
- QZTWVDCKDWZCLV-UHFFFAOYSA-N 1-isocyanato-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(N=C=O)C=C1 QZTWVDCKDWZCLV-UHFFFAOYSA-N 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- LRMSQVBRUNSOJL-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)F LRMSQVBRUNSOJL-UHFFFAOYSA-N 0.000 description 1
- WXJFKAZDSQLPBX-UHFFFAOYSA-N 2,2,3,3,4,4,4-heptafluorobutan-1-ol Chemical compound OCC(F)(F)C(F)(F)C(F)(F)F WXJFKAZDSQLPBX-UHFFFAOYSA-N 0.000 description 1
- WFELVFKXQJYPSL-UHFFFAOYSA-N 2,2,3,3,4,4,4-heptafluorobutanoyl chloride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(Cl)=O WFELVFKXQJYPSL-UHFFFAOYSA-N 0.000 description 1
- PJDOLCGOTSNFJM-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctan-1-ol Chemical compound OCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F PJDOLCGOTSNFJM-UHFFFAOYSA-N 0.000 description 1
- MPAMAEMOVKLPRB-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-henicosafluoroundecan-1-ol Chemical compound OCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F MPAMAEMOVKLPRB-UHFFFAOYSA-N 0.000 description 1
- RUDINRUXCKIXAJ-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-heptacosafluorotetradecanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RUDINRUXCKIXAJ-UHFFFAOYSA-N 0.000 description 1
- CAKZCCWLOCDNJK-UHFFFAOYSA-N 2,2,3,3,5,5,6,6,8,8,9,9,11,11,12,12,14,14,15,15-icosafluoro-1,4,7,10,13-pentaoxacyclopentadecane Chemical compound FC1(F)OC(F)(F)C(F)(F)OC(F)(F)C(F)(F)OC(F)(F)C(F)(F)OC(F)(F)C(F)(F)OC1(F)F CAKZCCWLOCDNJK-UHFFFAOYSA-N 0.000 description 1
- WFNRNCNCXRGUKN-UHFFFAOYSA-N 2,3,5,6-tetrafluoroterephthalic acid Chemical compound OC(=O)C1=C(F)C(F)=C(C(O)=O)C(F)=C1F WFNRNCNCXRGUKN-UHFFFAOYSA-N 0.000 description 1
- RIRBAVAYPRSMRH-UHFFFAOYSA-N 2,4-dimethoxy-1,3,5-triazine Chemical compound COC1=NC=NC(OC)=N1 RIRBAVAYPRSMRH-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical group C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 1
- RAZLJUXJEOEYAM-UHFFFAOYSA-N 2-[bis[2-(2,6-dioxomorpholin-4-yl)ethyl]azaniumyl]acetate Chemical compound C1C(=O)OC(=O)CN1CCN(CC(=O)O)CCN1CC(=O)OC(=O)C1 RAZLJUXJEOEYAM-UHFFFAOYSA-N 0.000 description 1
- SYZRZLUNWVNNNV-UHFFFAOYSA-N 2-bromoacetyl chloride Chemical compound ClC(=O)CBr SYZRZLUNWVNNNV-UHFFFAOYSA-N 0.000 description 1
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 1
- HVFQJWGYVXKLTE-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HVFQJWGYVXKLTE-UHFFFAOYSA-N 0.000 description 1
- ZZTAHKATRATLPG-UHFFFAOYSA-N 3-chloro-1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-5-(trifluoromethyl)pyridin-2-one Chemical compound ClC1=CC(C(F)(F)F)=CN=C1N1C(=O)C(Cl)=CC(C(F)(F)F)=C1 ZZTAHKATRATLPG-UHFFFAOYSA-N 0.000 description 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
- MEXUTNIFSHFQRG-UHFFFAOYSA-N 6,7,12,13-tetrahydro-5h-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one Chemical compound C12=C3C=CC=C[C]3NC2=C2NC3=CC=C[CH]C3=C2C2=C1C(=O)NC2 MEXUTNIFSHFQRG-UHFFFAOYSA-N 0.000 description 1
- HRNOIAOFVVUYJU-UHFFFAOYSA-N 7-amino-3-methylchromen-2-one Chemical compound C1=C(N)C=C2OC(=O)C(C)=CC2=C1 HRNOIAOFVVUYJU-UHFFFAOYSA-N 0.000 description 1
- XROXHZMRDABMHS-UHFFFAOYSA-N 7-fluoro-2,1,3-benzoxadiazole-4-sulfonamide Chemical compound NS(=O)(=O)C1=CC=C(F)C2=NON=C12 XROXHZMRDABMHS-UHFFFAOYSA-N 0.000 description 1
- CCKWMCUOHJAVOL-UHFFFAOYSA-N 7-hydroxy-4-(trifluoromethyl)chromen-2-one Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(O)=CC=C21 CCKWMCUOHJAVOL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical class CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical class CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- JRARNCFPLRONAE-UHFFFAOYSA-N O=C(c(c(F)c(c(C(NC(C=CC1C(C(F)(F)F)=C2)=CC1OC2=O)=O)c1F)F)c1F)NCCc(cc1)ccc1S(NC(NC1CCCCC1)=O)(=O)=O Chemical compound O=C(c(c(F)c(c(C(NC(C=CC1C(C(F)(F)F)=C2)=CC1OC2=O)=O)c1F)F)c1F)NCCc(cc1)ccc1S(NC(NC1CCCCC1)=O)(=O)=O JRARNCFPLRONAE-UHFFFAOYSA-N 0.000 description 1
- KUDRICPOVIPMAU-UHFFFAOYSA-N OC(CN(CCN(CC(O)=O)CC(O)=O)CC(Cc(cc1)ccc1NC(NS(C1C=CC(CCNC(c(c(F)c(c(F)c2F)F)c2F)=O)=CC1)(=O)=O)=O)N(CC(O)=O)CC(O)=O)=O Chemical compound OC(CN(CCN(CC(O)=O)CC(O)=O)CC(Cc(cc1)ccc1NC(NS(C1C=CC(CCNC(c(c(F)c(c(F)c2F)F)c2F)=O)=CC1)(=O)=O)=O)N(CC(O)=O)CC(O)=O)=O KUDRICPOVIPMAU-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 238000007466 Percutaneous biliary drainage Methods 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 229940123468 Transferase inhibitor Drugs 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 238000005693 aromatic fluorination reaction Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical compound C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- PBWZKZYHONABLN-UHFFFAOYSA-N difluoroacetic acid Chemical compound OC(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-N 0.000 description 1
- LTVOKYUPTHZZQH-UHFFFAOYSA-N difluoromethane Chemical group F[C]F LTVOKYUPTHZZQH-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 150000002221 fluorine Chemical class 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical compound [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 229950005514 glycyclamide Drugs 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000009217 hyperthermia therapy Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229950008446 melinamide Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- PBMIETCUUSQZCG-UHFFFAOYSA-N n'-cyclohexylmethanediimine Chemical compound N=C=NC1CCCCC1 PBMIETCUUSQZCG-UHFFFAOYSA-N 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- YZERDTREOUSUHF-UHFFFAOYSA-N pentafluorobenzoic acid Chemical compound OC(=O)C1=C(F)C(F)=C(F)C(F)=C1F YZERDTREOUSUHF-UHFFFAOYSA-N 0.000 description 1
- UXPOJVLZTPGWFX-UHFFFAOYSA-N pentafluoroethyl iodide Chemical compound FC(F)(F)C(F)(F)I UXPOJVLZTPGWFX-UHFFFAOYSA-N 0.000 description 1
- 229950008618 perfluamine Drugs 0.000 description 1
- YPJUNDFVDDCYIH-UHFFFAOYSA-N perfluorobutyric acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)F YPJUNDFVDDCYIH-UHFFFAOYSA-N 0.000 description 1
- BPHQIXJDBIHMLT-UHFFFAOYSA-N perfluorodecane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F BPHQIXJDBIHMLT-UHFFFAOYSA-N 0.000 description 1
- PCIUEQPBYFRTEM-UHFFFAOYSA-N perfluorodecanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F PCIUEQPBYFRTEM-UHFFFAOYSA-N 0.000 description 1
- CXGONMQFMIYUJR-UHFFFAOYSA-N perfluorododecanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CXGONMQFMIYUJR-UHFFFAOYSA-N 0.000 description 1
- UZUFPBIDKMEQEQ-UHFFFAOYSA-N perfluorononanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F UZUFPBIDKMEQEQ-UHFFFAOYSA-N 0.000 description 1
- YVBBRRALBYAZBM-UHFFFAOYSA-N perfluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YVBBRRALBYAZBM-UHFFFAOYSA-N 0.000 description 1
- CXZGQIAOTKWCDB-UHFFFAOYSA-N perfluoropentanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CXZGQIAOTKWCDB-UHFFFAOYSA-N 0.000 description 1
- RVZRBWKZFJCCIB-UHFFFAOYSA-N perfluorotributylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RVZRBWKZFJCCIB-UHFFFAOYSA-N 0.000 description 1
- JAJLKEVKNDUJBG-UHFFFAOYSA-N perfluorotripropylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F JAJLKEVKNDUJBG-UHFFFAOYSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- FCTRVTQZOUKUIV-MCDZGGTQSA-M potassium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound [K+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O FCTRVTQZOUKUIV-MCDZGGTQSA-M 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- PWEBUXCTKOWPCW-UHFFFAOYSA-N squaric acid Chemical class OC1=C(O)C(=O)C1=O PWEBUXCTKOWPCW-UHFFFAOYSA-N 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- QHMQWEPBXSHHLH-UHFFFAOYSA-N sulfur tetrafluoride Chemical compound FS(F)(F)F QHMQWEPBXSHHLH-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- SMBZJSVIKJMSFP-UHFFFAOYSA-N trifluoromethyl hypofluorite Chemical compound FOC(F)(F)F SMBZJSVIKJMSFP-UHFFFAOYSA-N 0.000 description 1
- WRTMQOHKMFDUKX-UHFFFAOYSA-N triiodide Chemical compound I[I-]I WRTMQOHKMFDUKX-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
- C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
- C07D285/28—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Description
本発明は新規なイメージングプローブおよび前記プローブを診断のイメージングプロセスおよび生理的な機能を決定する他のイメージングプロセスに使用する方法に関する。
糖尿病は巨大な比率の壊滅的な自己免疫性疾患である。それはグルコ−スの代謝不全によって特徴づけられ、とりわけ糖尿病患者の血液グルコ−スレベルの上昇に至る(高血糖症)。糖尿病はタイプ1、すなわち、患者のβ−細胞が膵腺においてインシュリンを産生するのをやめる場合に発生するインシュリン依存性糖尿病(IDDM)と、タイプ2、すなわち、インシュリン代謝の弱った患者およびβ−細胞の機能不全の患者に起こるインシュリン非依存性糖尿病(NIDDM)に分類される。NIDDMは通常進行するのに数10年かかり、順次高インシュリン血症、トリグリセリド濃度の上昇、高濃度血液グルコ−スおよび最後に末期のβ−細胞の機能麻痺へとすすみ、この段階ではインシュリンレベルは急激に低下し、通常患者へのインシュリン投与が必要となる。IDDMの患者においては、β−細胞はリンパ球の浸透を含む自己免疫のプロセスによって選択的に破壊される。NIDDMの初期の段階においては、インシュリンをもっと多くとの需要に応えるべくβ−細胞の量は増加する。それからNIDDMが進行するのにつれてβ−細胞の量の減少が起こる可能性がある。
本発明はイメージングプローブ、診断薬およびコントラスト薬として有用なフッ素化したおよび常磁性の抗糖尿病薬類似物(式I−XVII)に関する。さらに、本発明は本発明の式I〜XVIIの化合物を用いるイメージング方法に関する
本発明のフッ素化した常磁性の抗糖尿病薬類似物は下記一般式I〜XVIIの化合物を含む:
式1においては:R1=H、X;R2=H、X;R3=H、X;R4=H、X
式IIにおいては:R1=H、X;R2=H、X;R3=H、X;R4=H、X;R5=H、X
式IIIにおいては:
R1=H、X;R2=H、X;R3=H、X;R4=H、X;R5=H、X;R6=H、X;R7=H、X;R8=H、X;R9=H、X;R10=CO、CHF、CF2、CNX、X;R11=H、C(R7)3、X
式Vにおいては:R1=H、X;R2=H、X;R3=H、X;R4=H、X;R5=H、X;R6=H、X;R7=H、X
式VIにおいては:R1=H、X;R2=H、X、NH2、NHX、NX2;R3=H、X;R4=H、X
式VIIIにおいては:R1=H、X;R2=H、X;R3=H、X;R4=H、X;R5=H、X;R6=H、X;R7=H、X
式IXにおいては:R1=H、X;R2=H、X、(CH2)2NHCONHX;R3=H、X、OX;R4=H、X
ここでvは6−9、kは0−11、hは1−12、dは0−4である
式XIにおいては:R1=H、X;R2=H、X、NH2、NHX、NX2;R3=H、X;R4=H、X;R5=H、X;R6=H、X;R7=H、X;R8=OH、X
式XIIにおいては:R1=H、X;R2=H、X、NH2、NHX、NX2;R3=H、X;R4=H、X;R5=H、X;R6=H、X;R7=H、X;R8=OH、X
式XIVにおいては:R1=H、X;R2=H、X;R3=H、X;R4=H、X;R5=H、X;R6=H、X;R7=H、X;R8=H、X;R9=H、X;R10=H、X;R11=H、CH3、CH2X、X、NHX、CH2NHX;R12=CH3、CH2X、X、NHX、CH2NHX
式XVにおいては:R1=H、X、NH2、NHX、NX2;R2=H、X;R3=H、X;R4=H、X、NH2、NHX、NX2;R5=H、X;R6=H、X;R7=H、X
式XVIにおいては:R1=H、X、NH2、NHX、NX2;R2=H、X;R3=H、X;R4=H、X;R5=H、X;R6=H、X;R7=H、X
X=フルオロアルキル、フルオロアリ−ル、フルオロアシル、パ−フルオロアルキル、パ−フルオロアリ−ル、パ−フルオロアシル、パ−フルオロポリマー、フルオロアミン、フルオロカルバメ−ト、フルオロトリアジン、フルオロスルフォニルアルキル誘導体、F、CF3、COCxFy、CxFyHz、([CH2]mO)x(CH2CF2O)y(CF2CF2O)z(CF2)2CF2CH2O(CH2)pOH、CH2C(OH)CxFyHz、CxFyHzOp、COCxFyHz、OCH2CxFz[CxFzO]mF、CH2C(CH3)CO2CxHz(CF2)mCF3、CH2(CF2O)x(CF2CF2O)y(CF2O)zCF2CH2OH、CF2Cl、SO2[CF2]xCF3、NHCxFyHzOp、CH2CF2O[CF2CF2O]m(CF2OCF2CH2OH、COCxHz(CF)mCF3、COCF2O[CF2CF2O]nCF2OCF2CO2H、CO−CF(CF3)−[CF(CF3)CF2O]mF([CH2]mO)x(CH2CF2O)y(CF2CF2O)zCF2CH2O(CH2)pOH、N[CxFyHz]p、CxHzCO2CxHz(CF2)mCF3、COCxFy[CpFzO]mF、ルミネセントの残基、蛍光性の残基、フッ素化したルミネセントの残基またはフッ素化した蛍光性の残基であり、m、x、p、y、zは1〜150の整数であり、mはより好ましくは10〜100、もっとも好ましくは10〜50である。またx、p、y、zはより好ましくは10〜75、更に好ましくは10〜50、もっとも好ましくは10〜20である。上の式においてアシルおよびアルキル残基は、Ck(kは2〜100、より好ましくは2〜50、もっとも好ましくは2〜20)の鎖を持った飽和または不飽和の脂肪族残基を含む脂肪親和性部分、およびベンジル、ビフェニル、フェニル多環式芳香族、およびヘテロ原子を含む芳香族を含むアリール部位を含む芳香族部位、を含んでいる。そして
R1=XO、X、XNH、R4[O(CH2)2]mO、YM;T=CH2NH、CO2、O、S2、CONH、NHCO、X、NHCOX、R4[O(CH2)2]mO、CH2CO(CH2)2;R2=(CH2)2C6H6、CH2NH(CH2)2C6H6、CONH(CH2)2C6H6、X、NHX;R3=シクロヘキシル、アリ−ル、X、YM;R4=H、OH、YM、R1であり、
M=遷移金属またはランタニド列の任意の常磁性のイオンであり、ガドリニウム(III)、鉄(III)、マンガン(IIおよびIII)、クロム(III)、銅(II)、ジスプロシウム(III)、テルビウム(III)、ホルミウム(III)、エルビウム(III)、およびユウロピウム(III);最も好ましくはガドリニウム(III)、ジスプロシウム(III)、鉄(III)、およびマンガン(II)が含まれる。
本発明を実施するに当たり、本発明の新規なフッ素化化合物はそれぞれのスタ−ト物質(抗糖尿病の薬剤、骨格または置換基)を下記のような通常のフッ素化化学を用いてフッ素残基で処理することによって得られる。常磁性の抗糖尿病の化合物は常磁性のイオンと、常磁性のイオンと塩または錯体を形成しうる抗糖尿病の薬剤とを反応させることによって得られる。
a.フッ素を含有する抗糖尿病薬物類似物または常磁性の抗糖尿病薬物類似物を患者に対して治療薬量投与し;
b.患者を抗糖尿病薬物の活動部位である組織/器官のMRIに供し;
c.MRIイメ−ジから抗糖尿病薬の機能を評価すること
を含む。
a.フッ素含有抗糖尿病薬物類似物または常磁性の含有抗糖尿病薬物類似物を患者に治療薬量投与し;
b.経時的に患者を抗糖尿病薬物の活動部位である組織/器官のMRIに供し;
c.経時的にMRIイメ−ジから糖尿病の進行を評価すること
を含む。
本発明の常磁性のスルフォニルウレア錯体は適度に活性化した金属錯体残基、たとえば、1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラ酢酸モノ(p−アミノアニリド)[DOTA−p−NH2−アニリド]、5−アミノ−2−メトキシフェニル−1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラ酢酸、2−p−アミノベンジル−1,4,7,10−テトラアザシクロド−デカン−1,4,7,10−テトラ酢酸、p−アミノベンジル−ジエチレントリアミンペンタ酢酸、p−イソチオシアナ−トベンジル−1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラ酢酸、p−イソチオシアナ−ト−ベンジルジエチレントリアミンペンタ酢酸、p−イソチオシアナ−トベンジル−ジエチレントリアミンペンタ酢酸[p−SCN−Bz−DTPA]、1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラ酢酸モノ(N−ヒドロキシ琥珀酸イミドエステル)、1,4,7,10−テトラアザシクロドデカン−1,4,7−トリス(酢酸−t−ブチルエステル)−10−酢酸[DOTA−トリス(t−ブチルエステル)]、ジエチレントリアミンペンタ酢酸(DTPA)ジ酸無水物、または文献に報告されている他の金属錯体残基、たとえば、スクアリン酸(squaric aid)誘導体である、10−(2−エトキシ−3,4−ジオキソ−1−シクロブテニル)−1,4,7,10−テトラアザシクロドデカン−1,4,7−トリ酢酸(AimeらのBioconjugate Chemistry, 10,192−199,1999)を用いることによって調製することができる。アミン官能性の錯体残基は適当なカルボキシル基を含んだ合成単位と縮合することができ、DTPAジ酸無水物または1個のフリーカルボキシル基を持つ残基、たとえば、DOTA−トリス(t−ブチルエステル)は容易に活性化して各種の求核試薬と反応することができる(たとえば、the attachment of DOTA to an amine residue;Bhoradeら、Bioconjugate Chemistry,11,:301−305,2000).同様に、イソチオシアナ−トまたはイソシアナ−トの金属錯化誘導体、たとえばp−SCN−Bz−DTPA、は下記実施例2に示したようにスルフォニルウレアコアを調製するのに用いることができる。
ジフルオログリメピリド(difluoro Glimepiride)
グリメピリドの乾燥トルエン溶液にDEOXO−FLUOR(C6H4F3NO2S、6当量)を雰囲気温度で滴下した。反応混合物を2時間攪拌し、濃縮してアセトンに加えた。得られた褐色の固体をエ−テルで洗浄し、乾燥して、シリカゲルによるクロマトグラフィ−の後3−エチル−2,5−ジヒドロ−4−メチル−N−[2{4−[[[(トランス−4−メチルシクロヘキシル)アミノ]カルボニル]アミノ]スルフォニル]フェニル]エチル]−2,2−ジフルオロ−1H−ピロ−ル−1−N−カルボキサミドを得た。
C24H34F2N4O4S 分子量:512.61
計算値C、56.23;H、6.69;F、7.41;N、10.93;S、6.26
実測値C、56.01;H、7.05;F、7.18;N、10.71;S、6.23
ポリテトラフルオロエチレンオキサイド−コ−ジフルオロメチレンオキサイド−α−トリルウレタン−ω−トリルイソシアナ−トグリメピリド
グリメピリドの乾燥トルエン溶液にポリテトラフルオロエチレンオキサイド−コ−ジフルオロメチレンオキサイド−α、ω−ジイソシアナ−ト(Mw〜2,000、0.2当量)を雰囲気温度で滴下した。反応混合物を2時間攪拌し、濃縮して、アセトンに加えた。得られた白色固体をエ−テルで洗浄し、乾燥して、パ−フルオロポリマーでラベルされた3−エチル−2,5−ジヒドロ−4−メチル−N−[2{4−[[[(トランス−4−メチルシクロヘキシル)アミノ]カルボニル]アミノ]スルフォニル]フェニル]エチル]−2−オキソ−1H−ピロ−ル−1−カルボキサミドを得た。
C53H48F24N7O17S 分子量:1543.01
計算値C、41.25;H、3.14;F、29.55;N、6.35;S、2.08
実測値C、40.90;H、3.34;F、29.67;N、6.23;S、1.98
ヘプタフルオロブチリルメトフォルミン(Metformin)
メトフォルミンの乾燥トルエン溶液にゆっくり無水ヘプタフルオロ酪酸無水物(1.2当量)を加え、雰囲気温度で4時間攪拌した。水を加えて反応を停止し、反応混合物をアセトンで沈殿させた。粗フッ素化メトフォルミンをシリカゲルでクロマトグラフし、N−ヘプタフルオロブチリルN,N’−ジメチルイミドジカルボンイミドジアミドを得た。
C8H10F7N5O 分子量:325.19
計算値 C、29.55;H、3.10;F、40.90;N、21.54
実測値 C、29.35;H、3.42;F、40.65;N、21.18
7−アミノ−4−(トリフルオロメチル)クマリングリメピリド
グリメピリドのメチレンクロライド溶液に7−アミノ−4−(トリフルオロメチル)−クマリン(1.2当量)とナトリウムシアノボロハイドライド(7.2当量)を雰囲気温度で加えた。反応混合物を12時間攪拌し、濃縮し、シリカゲルによるクロマトグラフィ−によって3−エチル−2,5−ジヒドロ−4−メチル−N−[2{4−[[[(トランス−4−メチルシクロヘキシル)−アミノ]カルボニル]アミノ]スルホニル]フェニル]エチル]−2−[7−アミノ−4−(トリフルオロメチル)−クマリン]−1H−ピロール−1−カルボキサミドを得た。
C34H42F3N5O6S 分子量:705.79
計算値C、57.86;H、6.00;F、8.08;N、9.92;S、4.54
実測値C、57.61;H、6.05;F、8.18;N、9.71;S、4.23
ヘプタフルオログリブリド(Glyburide)類似物
ステップ1:4−カルボキシ−2,3,5,6−テトラフルオロフェニル−N−[[[(シクロヘキシルアミノ)カルボニル]アミノ]−スルフォニル)−フェニル]エチル]ベンズアミド
2,3,5,6−テトラフルオロテレフタル酸とジシクロヘキシルカルボジイミド(1.2当量)のメチレンクロライド溶液に4−(2−アミノエチル)ベンゼンスルフォンアミド(1.0当量)を雰囲気温度で加え16時間おいた。次いで反応生成物をシクロヘキシルイソシアナ−ト(1.1当量)および塩基(1.5M NaOH)で12時間処理し、所望の中間体Aを提供した。
C23H23F4N3O6S分子量:545.50
計算値C、50.64;H、4.25;F、13.93;N、7.70;S、5.88
実測値C、50.32;H、4.35;F、13.55;N、7.41;S、5.75
ステップ1からの中間体Aを2,2,2−トリフルオロエチルアミン(1.0当量)及びジシクロヘキシルカルボジイミド(1.2当量)で16時間処理し、シリカゲルによるクロマトグラフィ−によって目標生成物を得た。
C25H25F7N4O5S 分子量:626.54
計算値C、47.92;H、4.02;F、21.23;N、8.94;S、5.12
実測値C、47.65;H、3.78;F、21.11;N、8.76;S、5.02
2,3,4,5,6−ペンタフルオロフェニル−N−[2−(4−〔〔〔(シクロヘキシルアミノ]カルボニル〕アミノ〕−スルフォニル)フェニル]エチル]ベンズアミド
実施例5のステップ1で説明した方法で2,3,5,6−テトラフルオロテレフタル酸の代わりにペンタフルオロ安息香酸を用いて所望のグリブリド類似物を提供した。
C22H22F5N3O4S 分子量:519.49
計算値C、50.86;H、4.27;F、18.29;N、8.09;S、6.17
実測値C、50.64;H、4.05;F、18.05;N、7.63;S、5.78
3、5−ジ(トリフルオロメチル)フェニル−N−[2−(4−[[[(シクロヘキシルアミノ]カルボニル]アミノ]−スルフォニル)−フェニル]エチル]ベンズアミド
実施例5で説明した方法で2,3,5,6−テトラフルオロテレフタル酸の代わりに3,5−ジ(トリフルオロメチル)安息香酸を用いて所望のグリブリド類似物を提供した。
C24H25F6N3O4S 分子量:565.53
計算値C、50.97;H、4.46;F、20.16;N、7.43;S、5.67
実測値C、50.68;H、4.17;F、20.00;N、7.21;S、5.27
2,3,4,5,6−ペンタフルオロ−N−[2−(4−[[[(2,3,4−トリフルオロフェニル]カルボニル]アミノ]−スルフォニル)フェニル]エチル]ベンズアミド
実施例5で説明した方法でシクロヘキシルイソシアナ−トの代わりに2,3,4−トリフルオロフェニルイソシアナ−トを用いて所望のグリブリド類似物を提供した。
C22H13F8N3O4S 分子量:567.05
計算値C、46.57;H、2.31;F、26.79;N、7.41;S、5.65
実測値C、46.14;H、2.05;F、26.46;N、7.14;S、5.35
2,3,4,5,6−ペンタフルオロ−N−〔2−(4−〔〔〔(2,3,4,5,6−ペンタフルオロフェニル]カルボニル〕−アミノ〕スルフォニル)フェニル]エチル〕ベンズアミド
実施例8で説明した方法で2,3,4−トリフルオロフェニルイソシアナ−トの代わりにペンタフルオロフェニルイソシアナ−トを用いて所望のグリブリド類似物を提供した。
C22H11F10N3O4S 分子量:603.39
計算値C、43.79;H、1.84;F、31.49;N、6.96;S、5.31
実測値C、43.43;H、2.02;F、31.33;N、6.66;S、5.36
ヘプタフルオロ蛍光性のスルフォニルウレア(グリブリド)類似物
実施例5の中間体AのDMSO溶液を7−アミノ−4−(トリフルオロメチル)クマリン(1.0当量)およびジシクロヘキシルカルボジイミド(1.2当量)と18時間処理し、シリカゲルによるクロマトグラフィ−の後、N−[7−アミノ−4−(トリフルオロメチル)クマリン]カルボキサミド−2,3,5,6−テトラフルオロフェニル]−N−[2−(4−[[[(シクロヘキシルアミノ]カルボニル]アミノ]スルフォニル)−2,3,5,6−テトラフルオロフェニル]エチル]−2−メトキシベンズアミドを生成した。
C33H29F7N4O7S 分子量:758.66
計算値C、52.24;H、3.85;F、17.53;N、7.38;S、4.23
実測値C、52.12;H、3.59;F、17.39;N、7.12;S、4.14
2,3,4,5,6−ペンタフルオロフェニル−N−[[[(4−トリフルオロメチルフェニル]カルボニル]−アミノ]スルフォニル)−4−トリフルオロメチルフェニル]エチルアミン
実施例5で説明した方法で、シクロヘキシルイソシアナ−トの代わりにα、α、α−トリフルオロ−p−トリルイソシアナ−トを用いて行い、所望のグリブリド類似物を得た。
C23H15F8N3O4S 分子量:581.44
計算値C、47.51;H、2.60;F、26.14;N、7.23;S、5.51
実測値C、47.19;H、2.55;F、26.25;N、7.21;S、5.39
[1,1−ジオキソ−6−(トリフルオロメチル)−1,2,3,4−テトラヒドロ−1λ−6−2−4−ベンザチアジアジン−7−スルフォニル)]−1−[3,5−ジ(トリフルオロメチル)フェニル]カルボキサミド
1,1−ジオキソ−6−(トリフルオロメチル)−1,2,3,4−テトラヒドロ−1λ−6−2−4−ベンザチアジアジン−7−スルフォンアミドのDMSO溶液を3,5−ジ(トリフルオロメチル)フェニルイソシアナ−ト(1.1当量)および塩基(1.5MNaOH)と12時間処理し、所望の生成物を提供した。
C17H11F9N4O5S2 分子量:586.41
計算値C、34.82;H、1.89;F、29.16;N、9.55;S、10.94
実測値C、34.54;H、1.55;F、29.15;N、9.29;S、10.56
N−[4−(1,4,7,10−テトラアザシクロドデカン−1,4,7,10−N,N’,N’’,N’’’−テトラ酢酸)−(p−アミノ−アニリド)カルボキサミド−2,3,5,6−テトラフルオロフェニル]−N−[2−(4−[[[(シクロヘキシルアミノ]カルボニル]−アミノ]−スルフォニル)]エチル]−2−メトキシベンズアミド
実施例5のステップ#1で概説したようにして調製した、4−カルボキシ−2,3,5,6−テトラフルオロフェニル−N−[[[(シクロヘキシルアミノ]カルボニル]アミノ]スルフォニル)フェニル]エチル]ベンズアミドのメチレンクロライド溶液に、1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラ酢酸モノ(p−アミノアニリド)(1.1当量)とジシクロヘキシルカルボジイミド(1.2当量)を16時間かけて雰囲気温度で加え、シリカゲルによるクロマトグラフィ−によって、所望のフッ素化DOTA生成物を得た。
C44H55F4N9O12S 分子量:1010.02
計算値C、52.32;H、5.49;F、7.52;N、12.48;S、3.17
実測値C、52.14;H、5.55;N、12.29
N−[1−(ジエチレントリアミン−N,N,N’,N’’,N’’−ペンタ酢酸)カルボキサミド−]−N−[2−(4−[[[(シクロヘキシル−アミノ]カルボニル]アミノ]スルフォニル)エチル]−2−メトキシベンズアミド
4−(2−アミノエチル)ベンゼンスルフォンアミドとシクロヘキシルイソシアナ−トから実施例5で説明したようにして得たスルフォニルウレアのメチレンクロライド溶液にジエチレントリアミンペンタ酢酸(DTPA)ジ無水物(1.05当量)を16時間かけて雰囲気温度で加え、シリカゲルによるクロマトグラフィ−の後所望のDTPA生成物を得た。
C29H45N6O12S 分子量:701.77
計算値C、49.63;H、6.46;N、11.98;S、4.57
実測値C、49.34;H、6.24;N、11.45
N−[2,3,4,5,6−ペンタフルオロフェニル)カルボキサミド−]−N−[2−(4−[[[(シクロヘキシルアミノ]−カルボニル]アミノ]スルフォニル)エチル]−2−p−フェニルメチル(ジエチレントリアミン−N,N,N,N’’,N’’−ペンタ酢酸)
2,3,4,5,6−ペンタフルオロ安息香酸およびジシクロヘキシルカルボジイミド(1.2当量)のメチレンクロライド溶液に4−(2−アミノエチル)ベンゼンスルフォンアミド(1.0当量)を16時間かけて雰囲気温度で加えた。反応生成物をp−イソチオシアナ−トベンジル−ジエチレントリアミンペンタ酢酸(1.05当量)および塩基(1.5MNaOH)と12時間処理し、所望のDTPA生成物を提供した。
C37H40F5N6O14S 分子量:919.80
計算値C、48.31;H、4.38;F、10.33;N、9.14;S、3.49
実測値C、48.12;H、4.22;N、9.05
常磁性のスルフォニルウレア錯体
実施例13−15に記載したスルフォニルウレア結合体の調製物を水性緩衝液に溶かしたpH6.5のものを、化学量論量のGd(OAc)3またはDyCl3とともにそれぞれ4時間熟成し、HPLCで精製するか、pHを8に合わせ遠心分離して所望の常磁性のスルフォニルウレア錯体を得た。錯化は溶媒の1H緩和速度(1/T1)を測定することによってモニターした。
6−カルボキサミド−{4−[1−アミド−[N,N−1,6−ヘキサンジアミン]−6−アミノ]−2,3,5,6−テトラフルオロフェニル−N−[[[(シクロヘキシルアミノ]カルボニル]アミノ]−スルフォニル)−フェニル]エチル]−ベンズアミド}−ポリテトラフルオロエチレンオキサイド−コ−ジフルオロメチレンオキサイド−α−トリルウレタン−ω−トリルイソシアナ−トプロピレングリコ−ルアルギネ−ト
ステップ1:ポリテトラフルオロエチレンオキサイド−コ−ジフルオロメチレンオキサイド−α−トリルウレタン−ω−トリルイソシアナ−トプロピレングリコ−ルアルギネ−ト
プロピレングリコ−ルアルギネ−ト(Mw〜700,000Da)のメタノ−ル溶液をポリテトラフルオロエチレンオキサイド−コ−ジフルオロメチレンオキサイド−α,ω−ジイソシアナ−ト(Mw〜3,000、0.6当量)で処理し、生成した粘凋なペ−ストを雰囲気温度で6時間攪拌した。反応混合物をアセトンで沈殿させ、アセトンで洗浄し、濾過し、透析し乾燥して、F29.99%のパ−フルオロポリマ−でラベルしたアルギネ−トを生成した。
4−カルボキシ−2,3,5,6−テトラフルオロフェニル−N−[[[(シクロヘキシルアミノ]カルボニル]アミノ)−スルフォニル)−フェニル]エチル]ベンズアミド(ステップ1、実施例5)のアセトン溶液を1、3−ジイソプロピルカルボジイミド(1.1当量)と1時間、次いで1,6−ヘキサンジアミン(1.1当量)と6時間処理した。前記物質をシリカゲルクロマトグラフィ−で精製し、生成したアミノ化したグリブリド生成物をステップ1のパ−フルオロポリマーでラベルしたアルギネ−ト(1.1当量)とメタノ−ル水溶液中で16時間縮合し、透析後F21.45%のポリマ−のフッ素化したグリブリドを得た。
本発明の常磁性の抗糖尿病化合物は生体内でのMRイメージングおよび磁気共鳴血管造影のコントラスト向上剤として用いることができる。コントラスト剤は生理的緩衝液または他の生理的に許容される、当業者によく知られている媒体に溶かして経口、脈管内または腹腔内で投与される。投与量はNMRイメージング装置の感度およびコントラスト薬剤組成物に依存する。高い常磁性の物質、たとえば、ガドリニウム(III)、を含むコントラスト薬剤は一般的に低い磁気モーメントを持った常磁性の物質、たとえば、鉄(III)を含むコントラスト薬剤よりも投与量が少なくて済む。一般的に、投与量は約0.001〜1mmol/kg、好ましくは約0.01〜0.1mmol/kgの範囲となる。ひとつの実施形態では、生成物を標準の生理食塩水のような適当な注入媒体中に分散して分散液を形成し、その分散液を静脈内注射によって患者の脈管システムに導入する。粒子は脈管システムを通って標的器官に運ばれ、取り込まれる。次いで生理的な機能を決定するためにMRI走査が行われる。
参考文献
1.米国特許6,019,959、2000年2月1日、Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis
発明者 Platzek,Johannes;Niedballa,Ulrich;Raduchel,Bernd;Schlecker,Wolfgang;Weinmann,Hanns−Joachim;Frenzel,Thomas;Misselwitz,Bernd;Ebert,Wolfgang
譲受人 Schering Aktiengesellschaft
2.米国特許6,011,048、2000年1月4日、Thiazolebenzenesulfonamides as β− agonists for treatment of diabetes and obesity
発明者 Mathvink;Robert J.;Parmee;Emma R.;Tolman;Samuel;Weber;Ann E.
譲受人 Merck & Co.,Inc.
3.米国特許5,510,496、1996年4月23日、Substituted pyrazolylbenzenesulfonamides
発明者 Talley;John J.;Penning;Thomas D.;Collins;Paul W.;Malecha;James W.;Bertenshaw;Stephen R.;Graneto;Matthew J.
譲受人 G.D.Searle & Co.
4.米国特許5,342,823、1994年8月30日、Sulfonylureas
発明者 Kuhimeyer;Rainer;Topfl;Werner;Fory;Werner
譲受人 Ciba−Geigy Corporation
5.米国特許6,218,464、2001年4月17日、Preparation of fluorinated polymers
発明者 Parker;Hsing−Yeh;Lau;Willie;Rosenlind; Erik S.
譲受人 Rohm and Haas Company
6.米国特許5,798,406、1998年8月25日、 Fluorinated acrylic and methacrylic latices and mixtures thereof, processes for manufacturing them and their applications in the field of hydrophobic coatings
発明者 Feret;Bruno;Sarrazin;Laure;Vanhoye;Didier
譲受人 Elf Atochem S. A
7. PCT WO00/40252,2000年、 Hetero−polysaccharide conjugate and methods of making and using the same
発明者 C.Fraker,L.Invaeradi,M.Mares−Guia,C.Ricordi
譲受人 Biomm,Inc.およびUniversity of Miami
Claims (8)
- 一般式I〜XVIIから選ばれた構造を持つフッ素化した抗糖尿病化合物;
式Iにおいては:
R1はH、Xを表し、R2はH、Xを表し、R3はH、Xを表し、R4はH、Xを表し、
式IIにおいては:
R1はH、Xを表し、R2はH、Xを表し、R3はH、Xを表し、R4はH、Xを表し、R5はH、Xを表し、
式IIIにおいては:
R1はH、Xを表し、R2はH、Xを表し、R3はH、Xを表し、R4はH、Xを表し、R5はH、Xを表し、R6はH、Xを表し、R7はH、Xを表し、R8はH、Xを表し、R9はH、Xを表し、R10はCO、CHF、CF2、CNX、Xを表し、R11はH、C(R7)3、Xを表し、
式IVにおいては:
R1はH、Xを表し、R2はH、Xを表し、R3はH、Xを表し、R4はH、Xを表し、R5はH、Xを表し、R6はH、Xを表し、
式Vにおいては:
R1はH、Xを表し、R2はH、Xを表し、R3はH、Xを表し、R4はH、Xを表し、R5はH、Xを表し、R6はH、Xを表し、R7はH、Xを表し、
式VIにおいては:
R1はH、Xを表し、R2はH、X、NH2、NHX、NX2を表し、R3はH、Xを表し、R4はH、Xを表し、
式VIIにおいては:
R1はH、Xを表し、R2はH、Xを表し、R3はH、Xを表し、R4はH、Xを表し、R5はH、Xを表し、R6はH、Xを表し、
式VIIIにおいては:
R1はH、Xを表し、R2はH、Xを表し、R3はH、Xを表し、R4はH、Xを表し、R5はH、Xを表し、R6はH、Xを表し;R7はH、Xを表し、
式IXにおいては:
R1はH、Xを表し、R2はH、X、(CH2)2NHCONHXを表し、R3はH、X、OXを表し、R4はH、Xを表し、
式Xにおいては:
R1はXを表し、R2はCVHkFh、CVHkFhOd、C6HkFhR3を表し、R3はXを表し、ここでvは6〜9(両端の値を含む)、kは0〜11(両端の値を含む)、hは1〜12(両端の値を含む)、dは0〜4(両端の値を含む)であり、
式XIにおいては:
R1はH、Xを表し、R2はH、X、NH2、NHX、NX2を表し、R3はH、Xを表し、R4はH、Xを表し、R5はH、Xを表し、R6はH、Xを表し、R7はH、Xを表し、R8はOH、Xを表し、
式XIIにおいては:
R1はH、Xを表し、R2はH、X、NH2、NHX、NX2を表し、R3はH、Xを表し、R4はH、Xを表し、R5はH、Xを表し、R6はH、Xを表し、R7はH、Xを表し、R8はOH、Xを表し、
式XIIIにおいては:
R1はH、Xを表し、R2はH、Xを表し、R3はH、Xを表し、R4はH、Xを表し、R5はH、Xを表し、R6はH、Xを表し、R7はH、Xを表し、R8はH、Xを表し、R9はH、Xを表し、R10はH、CH2X、X、NHX、CH2NHXを表し、R11はH、Xを表し、R12はOH、OX、X、NHXを表し、
式XIVにおいては:
R1はH、Xを表し、R2はH、Xを表し、R3はH、Xを表し、R4はH、Xを表し、R5はH、Xを表し、R6はH、Xを表し、R7はH、Xを表し、R8はH、Xを表し、R9はH、Xを表し、R10はH、Xを表し、R11はH、CH3、CH2X、X、NHX、CH2NHXを表し、R12はCH3、CH2X、X、NHX、CH2NHXを表し、
式XVにおいては:
R1はH、X、NH2、NHX、NX2を表し、R2はH、Xを表し、R3はH、Xを表し、R4はH、X、NH2、NHX、NX2を表し、R5はH、Xを表し、R6はH、Xを表し、R7はH、Xを表し、
式XVIにおいては:
R1はH、X、NH2、NHX、NX2を表し、R2はH、Xを表し、R3はH、Xを表し、R4はH、Xを表し、R5はH、Xを表し、R6はH、Xを表し、R7はH、Xを表し、
ここで上の式I〜XVIにおいて:
X=フルオロアルキル、フルオロアリ−ル、フルオロアシル、パ−フルオロアルキル、パ−フルオロアリ−ル、パ−フルオロアシル、パ−フルオロポリマー、F、CF3、COCxFy、CxFyHz、([CH2]mO)x(CH2CF2O)y(CF2CF2O)z(CF2)2CF2CH2O(CH2)pOH、CH2C(OH)CxFyHz、CxFyHzOp、COCxFyHz、OCH2CxFz[CxFzO]mF、CH2C(CH3)CO2CxHz(CF2)mCF3、CH2(CF2O)x(CF2CF2O)y(CF2O)zCF2CH2OH、NHCxFyHzOp、CH2CF2O[CF2CF2O]m(CF2OCF2CH2OH、COCxHz(CF2)mCF3、CO−CF2O[CF2CF2O]nCF2OCF2CO2H、CO−CF(CF3)−[CF(CF3)CF2O]mF([CH2]mO)x(CH2CF2O)y(CF2CF2O)zCF2CH2O(CH2)pOH、N[CxFyHz]p、CxHzCO2CxHz(CF2)mCF3、COCxFy[CpFzO]mF、ルミネセント残基、蛍光性残基、フッ素化したルミネセント残基、あるいはフッ素化した蛍光性残基であり、m、x、p、y、zは1〜150の整数(両端の値を含む)であり、
式XVIIにおいて:
R1はXO、X、XNH、R4[O(CH2)2]mO、YMを表し、
TはCH2NH、CO2、O、S2、CONH、NHCO、X、NHCOX、R4[O(CH2)2]mO、CH2CO(CH2)2を表し、
R2は(CH2)2C6H6、CH2NH(CH2)2C6H6、CONH(CH2)2C6H6、X、NHXを表し、
R3はシクロヘキシル、アリ−ル、X、YMを表し、
R4はH、OH、YM、R1を表し、
Mは遷移金属またはランタニドの任意の常磁性のイオンを表し、
Xはフルオロアルキル、フルオロアリ−ル、フルオロアシル、パ−フルオロアルキル、パ−フルオロアリ−ル、パ−フルオロアシル、パ−フルオロポリマ−、F、CF3、COCxFy、CF3CO2、CXFyHz、([CH2]mO)x(CH2CF2O)y(CF2CF2O)z(CF2)2CF2CH2O(CH2)pOH、CH2C(OH)CxFyHz、CxFyHzOp、COCxFyHz、OCH2CxFz[CxFzO]mF、CH2C(CH3)CO2CxHz(CF2)mCF3、CH2(CF2O)x(CF2CF2O)y(CF2O)zCF2CH2OH、COCxHz(CF2)mCF3、NHCxFyHzOp、CH2CF2O[CF2CF2O]m(CF2OCF2CH2OH、CO−CF2O[CF2CF2O]nCF2OCF2CO2H、CO−CF(CF3)−[CF(CF3)CF2O]mF([CH2]mO)x(CH2CF2O)y(CF2CF2O)zCF2CH2O(CH2)pOH、CF3SO3、N[CxFyHz]p、CxHzCO2CxHz(CF2)mCF3、COCxFy[CpFzO]mF、ルミネセント残基、蛍光性残基、フッ素化したルミネセント残基またはフッ素化した蛍光性残基を表し、YはCH2C(OH)CH3を表し、m、p、x、y、zは1〜150(両端の値を含む)を表し、nは10〜10,000(両端の値を含む)であり、Yは1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラ酢酸モノ(p−アミノアニリド)、5−アミノ−2−メトキシフェニル−1,4,7,10−テトラアザシクロド−デカン−1,4,7,10−テトラ酢酸、2−p−アミノベンジル−1,4,7,10−テトラアザシクロド−デカン−1,4,7,10−テトラ酢酸、p−アミノベンジル−ジエチレントリアミンペンタ酢酸、p−イソチオシアナ−トベンジル−1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラ酢酸、p−イソチオシアナ−ト−ベンジルジエチレン−トリアミンペンタ酢酸、p−イソチオシアナ−トベンジルジエチレントリアミンペンタ酢酸、1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラ酢酸モノ(N−ヒドロキシ琥珀酸イミドエステル)、1,4,7,10−テトラアザシクロドデカン−1,4,7−トリス(酢酸-t−ブチルエステル)−10−酢酸、ジエチレントリアミン−ペンタ酢酸、1,4,7,10−テトラアザシクロドデカン、1,4,7−トリアザシクロノナン、1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラキス(メチレンフォスフォン酸)、および10−(2−エトキシ−3,4−ジオキソ−1−シクロブテニル)−1,4,7,10−テトラアザシクロドデカン−1,4,7−トリ酢酸からなる群から選択される多座配位金属錯体残基を表す。 - 次のa〜qからなる群から選ばれた請求項1のフッ素化した抗糖尿病化合物:
a.次式の6−カルボキサミド−{4−[1−アミド−[N,N−1,6−ヘキサンジアミン]−6−アミド]−2,3,5,6−テトラフルオロフェニル−N−[[[(シクロヘキシルアミノ]カルボニル]アミノ]−スルホニル)−フェニル]エチル]−ベンズアミド}−ポリテトラフルオロエチレンオキサイド−コ−ジフルオロメチレンオキサイド−α−トリルウレタン−ω−トリルイソシアナ−トプロピレングリコ−ルアルギネ−ト;
e.次式の[1,1−ジオキソ−6−(トリフルオロメチル)−1,2,3,4−テトラヒドロ−1□−6−2−4−ベンザチアジアジン−7−スルフォニル)]−[3、5−ジ(トリフルオロメチル)フェニル]カルボキサミド;
- 常磁性のイオンMがガドリニウム(III)、鉄(III)、マンガン(IIおよびIII)、クロム(III)、銅(II)、ジスプロシウム(III)、テルビウム(III)、ホルミウム(III)、エルビウム(III)、およびユウロピウム(III)からなる群から選択される請求項1記載のフッ素化抗糖尿病化合物。
- 式XXのアシルおよびアルキル残基が、kが2〜100であるCk鎖を持った飽和および不飽和脂肪族残基を含む親脂肪性部位を含み、アリール部位がベンジル、ビフェニル、フェニル、多環式芳香族およびヘテロ原子含有芳香族からなる群から選択される芳香族部位を含有する、請求項1記載のフッ素化抗糖尿病化合物。
- x、p、y、zおよびmがそれぞれ10〜50(両端の値を含む)の整数である請求項1記載のフッ素化抗糖尿病化合物。
- a.請求項1記載のフッ素化抗糖尿病化合物を患者に投与すること;
b.その患者MRIの操作を施すこと、;および
b.そのMRIの結果をその患者の以前のMRIの結果または基準となるMRIの結果と比較することによってその患者の糖尿病の病気の経過を評価すること
を含む患者の糖尿病の病気の経過を評価する方法。 - a.請求項1記載のフッ素化抗糖尿病化合物を患者に投与すること;
b.その患者MRIの操作を施すこと、;および
c.そのMRIの結果をその患者の以前のMRIの結果または基準となるMRIの結果と比較することによって抗糖尿病化合物の機能を評価すること
を含む抗糖尿病化合物の機能を評価する方法。 - a.請求項1記載の含フッ素抗糖尿病化合物を患者に治療の量だけ投与すること;
b.経時的にその患者を抗糖尿病薬物の作用場所である組織/器官のMRIに供すること;および
c.MRIイメ−ジを比較することによって、経時的に得られたMRIイメ−ジから糖尿病の進行を評価すること
を含む患者の糖尿病の進行をモニターする方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37271702P | 2002-04-11 | 2002-04-11 | |
PCT/US2003/011034 WO2003086563A2 (en) | 2002-04-11 | 2003-04-11 | Diabetes imaging probes |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005522495A true JP2005522495A (ja) | 2005-07-28 |
Family
ID=29250896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003583570A Pending JP2005522495A (ja) | 2002-04-11 | 2003-04-11 | 新規な糖尿病イメージングプローブ |
Country Status (4)
Country | Link |
---|---|
US (1) | US6911457B2 (ja) |
JP (1) | JP2005522495A (ja) |
AU (1) | AU2003224917A1 (ja) |
WO (1) | WO2003086563A2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008001851A1 (en) * | 2006-06-28 | 2008-01-03 | Ihi Corporation | Drug, drug induction device, magnetic detector and method of designing drug |
WO2009054327A1 (ja) * | 2007-10-22 | 2009-04-30 | Osaka Foundation For Trade And Industry | Mri用プローブ |
US9505732B2 (en) | 2008-11-20 | 2016-11-29 | Ihi Corporation | Auto magnetic metal salen complex compound |
US10034941B2 (en) | 2007-12-28 | 2018-07-31 | Ihi Corporation | Iron-salen complex |
JP2020520984A (ja) * | 2017-05-24 | 2020-07-16 | ザ ユニバーシティ オブ クィーンズランド | 新規な化合物及び使用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019034697A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
GB201803394D0 (en) * | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
CN109928897B (zh) * | 2019-04-01 | 2021-09-14 | 四川大学华西医院 | 防治梗死性疾病的双胍衍生物及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3507961A (en) * | 1963-10-19 | 1970-04-21 | Hoechst Ag | Benzenesulfonyl ureas as anti-diabetic agents |
JPS6118754A (ja) * | 1984-06-27 | 1986-01-27 | イーライ・リリー・アンド・カンパニー | ベンゼンスルホンアミド類およびその改良 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2961377A (en) | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
US3366650A (en) * | 1965-10-07 | 1968-01-30 | Squibb & Sons Inc | Tetra-and penta-fluoro-phenyl- and phenylalkyl-biguanides and salts thereof |
FR6786M (ja) * | 1967-08-10 | 1969-03-17 | ||
DE2009743A1 (de) * | 1970-03-03 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Substituierte Biguanide mit antihyperglykämischer Wirkung |
US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
DE3049665T1 (de) | 1979-06-25 | 1982-03-18 | Suntech | Use of perfluorocarbon as burn treatment |
US5236694A (en) * | 1990-02-21 | 1993-08-17 | The Board Of Regents, The University Of Texas System | 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents |
EP0558445A1 (de) | 1992-02-20 | 1993-09-01 | Ciba-Geigy Ag | Sulfonylharnstoffe als Herbizide |
US5608110A (en) * | 1993-06-15 | 1997-03-04 | Bracco International B.V. | Heteroatom-bearing ligands and metal complexes thereof |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
FR2725721B1 (fr) | 1994-10-18 | 1998-12-04 | Atochem Elf Sa | Latex et melanges de latex acryliques et methacyliques fluores, leurs procedes de fabrication et leurs applications dans le domaine des revetements hydrophobes |
US6011048A (en) | 1997-01-28 | 2000-01-04 | Merck & Co., Inc. | Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity |
TW494125B (en) | 1997-07-11 | 2002-07-11 | Rohm And Haas Compary | Preparation of fluorinated polymers |
US6019959A (en) | 1997-07-31 | 2000-02-01 | Schering Aktiengesellschaft | Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis |
ATE321562T1 (de) | 1999-01-04 | 2006-04-15 | Biomm Inc | Neue polymer zubereitungen enthaltende perluorierte verbindungen zur technischen handhabung von zellen und gewebe bei transplantationen, um den metabolismus und die überlebensrate der zellen zu verbessern, sowie verfahren zu deren herstellung |
-
2003
- 2003-04-11 WO PCT/US2003/011034 patent/WO2003086563A2/en active Application Filing
- 2003-04-11 AU AU2003224917A patent/AU2003224917A1/en not_active Abandoned
- 2003-04-11 US US10/411,970 patent/US6911457B2/en not_active Expired - Fee Related
- 2003-04-11 JP JP2003583570A patent/JP2005522495A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3507961A (en) * | 1963-10-19 | 1970-04-21 | Hoechst Ag | Benzenesulfonyl ureas as anti-diabetic agents |
JPS6118754A (ja) * | 1984-06-27 | 1986-01-27 | イーライ・リリー・アンド・カンパニー | ベンゼンスルホンアミド類およびその改良 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691261B2 (en) | 2005-08-31 | 2014-04-08 | Ihi Corporation | Drug, drug guidance system, magnetic detection system, and drug design method |
WO2008001851A1 (en) * | 2006-06-28 | 2008-01-03 | Ihi Corporation | Drug, drug induction device, magnetic detector and method of designing drug |
JP5378792B2 (ja) * | 2006-06-28 | 2013-12-25 | 株式会社Ihi | 磁性薬誘導システム |
WO2009054327A1 (ja) * | 2007-10-22 | 2009-04-30 | Osaka Foundation For Trade And Industry | Mri用プローブ |
US10034941B2 (en) | 2007-12-28 | 2018-07-31 | Ihi Corporation | Iron-salen complex |
US9505732B2 (en) | 2008-11-20 | 2016-11-29 | Ihi Corporation | Auto magnetic metal salen complex compound |
JP2020520984A (ja) * | 2017-05-24 | 2020-07-16 | ザ ユニバーシティ オブ クィーンズランド | 新規な化合物及び使用 |
JP7072586B2 (ja) | 2017-05-24 | 2022-05-20 | ザ ユニバーシティ オブ クィーンズランド | 新規な化合物及び使用 |
Also Published As
Publication number | Publication date |
---|---|
AU2003224917A1 (en) | 2003-10-27 |
US6911457B2 (en) | 2005-06-28 |
US20030207823A1 (en) | 2003-11-06 |
WO2003086563A2 (en) | 2003-10-23 |
WO2003086563A3 (en) | 2004-03-18 |
AU2003224917A8 (en) | 2003-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220127237A1 (en) | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | |
US9480687B2 (en) | Pyrazine derivatives and uses thereof in renal monitoring | |
US7030208B2 (en) | Biocompatible materials and probes | |
EP1989179B1 (en) | Contrast agents | |
JP2010018600A (ja) | ピラジン誘導体、その使用方法、およびその調製方法 | |
US7090829B2 (en) | Imaging probes | |
US7674902B2 (en) | Luminescent metal complexes for monitoring renal function | |
JPH06181890A (ja) | Mri造影剤 | |
JP2012512256A (ja) | 修飾ピラジン誘導体およびその使用 | |
US6911457B2 (en) | Diabetes imaging probes | |
US20090098059A1 (en) | Contrast agents | |
US20080267884A1 (en) | Contrast Agents and Diagnostic Compositions Based on Iodine-Containing Cyanuric Acid Derivatives | |
TW200400972A (en) | Biocompatible polymers and use as imaging probes | |
RU2599500C1 (ru) | Контрастирующий агент для введения фтор-19 метки в белки, содержащие остатки лизина | |
JP2011500532A (ja) | 造影剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060612 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090715 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091031 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091205 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100108 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100412 |